Silence Therapeutics plc SLN
Set alert
19.75 USD -0.05 -0.25%
At close
19.74 -0.01 -0.04%
Pre-market · Nov 2, 4:00 AM ET
19.74 Day range 19.80
4.19 52-week range 19.87
- YTD
- +224.84%
- 1 year
- +175.84%
- Open
- 19.74
- Prev close
- 19.80
- Mkt cap
- 1.23B
- Vol
- 621.43K
- Avg vol
- 2.77M
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.74
- High
- 19.80
- Forward P/E
- -51.97
- Beta
- 1.45
- Short ratio
- 2.70
- Inst. own
- 47.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.35
- 200-d avg
- 8.99
- 1y target
- 19.75
6M chart
Events in this range
- May 7, 2026Earnings: -0.32; estimate -0.33; surprise 3.03%
- Jun 17, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jun 24, 2026Rating: Cantor Fitzgerald · — → Overweight
- Aug 10, 2026Earnings: -0.26; estimate -0.13866; surprise -87.51%
- Aug 11, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 21, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (34)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| RSI: Overbought | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| RSI: Overbought | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
Key statistics
- Market cap
- 1.23B
- Enterprise value
- 863.54M
- Trailing P/E
- 0.00
- Forward P/E
- -51.97
- PEG ratio
- 0.00
- Price / sales
- 1997.58
- Price / book
- 24.26
- EPS (TTM)
- -1.29
- Beta
- 1.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 615.00K
- Revenue growth
- 0.00%
- Free cash flow
- -23.57M
- Total cash
- 72.05M
- Total debt
- 112.00K
- Return on equity
- -90.41%
- Shares outstanding
- 62.20M
- Short % of float
- 5.78%
- 50-day average
- 13.35
- 200-day average
- 8.99
Analyst view
Consensus: hold
Hold
Price target (mean) 19.75 0.0% upside
Now 19.75
- Target (low)
- 19.00
- Target (mean)
- 19.75
- Target (high)
- 20.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.09.
Financials — quick view
SLN Revenue — quarterly 0
SLN Net income — quarterly -12.27M
SLN EPS — quarterly -0.27
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.11289 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.13866 | -0.26 | -0.12 | -87.51% |
| May 7, 2026 | Mar 31, 2026 | -0.33 | -0.32 | +0.01 | +3.03% |
| Mar 5, 2026 | Dec 31, 2025 | -0.32 | -0.25 | +0.07 | +21.88% |
| Nov 6, 2025 | Sep 30, 2025 | -0.40 | -0.45 | -0.05 | -12.50% |
| Aug 7, 2025 | Jun 30, 2025 | -0.27 | -0.54 | -0.27 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 11, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jun 24, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Jun 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- silence-therapeutics.com
News
- HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
- Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
- Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
- Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Is Silence Therapeutics Stock Skyrocketing Monday?
- Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
- Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
- Merck KGaA Agrees To Acquire Silence Therapeutics For $20 Per ADS In Cash
Your note
Sign in to keep a note on SLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Siren, L.L.C. | 5.50% | 3,311,438 | 65.40M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.04% | 3,033,560 | 59.91M | Jun 29, 2026 |
| Redmile Group, LLC | 3.60% | 2,164,777 | 42.75M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 2.24% | 1,346,731 | 26.60M | Jun 29, 2026 |
| Citadel Advisors Llc | 2.21% | 1,329,625 | 26.26M | Jun 29, 2026 |
| Nextech Invest, Ltd. | 1.58% | 952,400 | 18.81M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 3.39% | 2,042,900 | 40.35M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.88% | 531,788 | 10.50M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.83% | 500,000 | 9.88M | Aug 30, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.48% | 289,972 | 5.73M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.38% | 228,000 | 4.50M | Aug 30, 2026 |
| ALGER FUNDS-Alger Small Cap Growth Fund | 0.18% | 105,679 | 2.09M | Jul 30, 2026 |